Ampio Pharmaceuticals (AMPE)
(Delayed Data from OTC)
$0.00 USD
0.00 (0.00%)
Updated Sep 12, 2024 12:37 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
Ampio Pharmaceuticals, Inc. [AMPE]
Reports for Purchase
Showing records 1 - 20 ( 39 total )
Company: Ampio Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Ampio Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Ampio Pharmaceuticals, Inc.
Industry: Medical - Drugs
1Q22: Exploring Various PotentialStrategic Alternatives, Cash Into 2H23
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Ampio Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Ampio Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Ampio Pharmaceuticals, Inc.
Industry: Medical - Drugs
Need for Another Phase 3 Ampion Trial Delays Revenue, PT to $2 from $4
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Ampio Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Ampio Pharmaceuticals, Inc.
Industry: Medical - Drugs
4Q21: FDA Clarity on Ampion Trials Likely By Mid-2022, Funded Into 2H23
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Ampio Pharmaceuticals, Inc.
Industry: Medical - Drugs
Potential for Ampion Approval If FDA Allows m-ITT Data & a Function Trend
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Ampio Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Ampio Pharmaceuticals, Inc.
Industry: Medical - Drugs
Reasons to Sit Down with These Biotech Managements at the 2022 Conference
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Ampio Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Ampio Pharmaceuticals, Inc.
Industry: Medical - Drugs
Expecting Pre-NDA Meeting & Disclosure of Trial AP-013 Results in 1H22
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Ampio Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Ampio Pharmaceuticals, Inc.
Industry: Medical - Drugs
3Q21: Ampion Trials Progressing Well,Can Fund Itself Through 1Q23
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Ampio Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Ampio Pharmaceuticals, Inc.
Industry: Medical - Drugs
Second Pivotal Ampion Trial Shows Statistically Significant Improvement
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J